trans-Nerolidol is a floral-woody sesquiterpene alcohol that shows up as a major composition marker in Siam wood and in many fragrance-bearing botanicals. Public evidence is strongest for identity, occurrence, formulation use, and preclinical activity, with additional mechanistic signals around membrane permeation and xenobiotic-enzyme modulation. The literature is promising but still mostly preclinical, so AromaForge should frame trans-nerolidol as a well-studied aroma constituent rather than a medical agent.
Chemical identity and composition
PubChem maps trans-nerolidol to the (6E) isomer of nerolidol with formula C15H26O and InChIKey FQTLCLSUCSAZDY-SDNWHVSQSA-N. In the AromaForge archive it is a defining Siam wood constituent, and a live supplier/GC context already used in the oil record places it at roughly 30.84% to 40.20% in Siam wood material. The broader nerolidol literature often discusses both cis and trans isomers together, so constituent-specific claims should stay modest unless a paper explicitly names trans-nerolidol.
Aroma and practical use
- Use the recorded woody, floral, tea-like, fresh bark descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2016 review summarized nerolidol as a naturally occurring sesquiterpene alcohol used in cosmetics and flavoring and collated mostly preclinical evidence for antimicrobial, antioxidant, anti-inflammatory, antiparasitic, and permeation-related activity.
A 2016 review summarized nerolidol as a naturally occurring sesquiterpene alcohol used in cosmetics and flavoring and collated mostly preclinical evidence for antimicrobial, antioxidant, anti-inflammatory, antiparasitic, and permeation-related activity.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
In mice, a single oral dose of trans-nerolidol increased CYP2B, CYP3A, and CYP2C activity and mRNA levels in liver and small intestine, indicating meaningful xenobiotic-metabolism effects.
In mice, a single oral dose of trans-nerolidol increased CYP2B, CYP3A, and CYP2C activity and mRNA levels in liver and small intestine, indicating meaningful xenobiotic-metabolism effects.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A breast cancer model reported that trans-nerolidol increased intracellular doxorubicin accumulation and reduced migration in vitro, but the same combination did not improve tumor-growth inhibition in tumor-bearing mice.
A breast cancer model reported that trans-nerolidol increased intracellular doxorubicin accumulation and reduced migration in vitro, but the same combination did not improve tumor-growth inhibition in tumor-bearing mice.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025 rat study reported that trans-nerolidol protected against isoproterenol-induced myocardial ischemia and downregulated cytochrome-c and caspase-related apoptotic signaling, but this remains animal evidence.
A 2025 rat study reported that trans-nerolidol protected against isoproterenol-induced myocardial ischemia and downregulated cytochrome-c and caspase-related apoptotic signaling, but this remains animal evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot assessed
Not assessed in the available record.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot assessed
Not assessed in the available record.
Penetration enhancementNot assessed
Not assessed in the available record.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The nerolidol review describes toxicological and pharmacokinetic discussion but does not establish a simple consumer-facing dermal limit specific to the trans isomer.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because trans-nerolidol modulated CYP-related enzymes in mice and CYP3A4 in vitro, benefit-oriented copy should avoid implying universal compatibility with drugs or supplements.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No human clinical efficacy evidence specific to isolated trans-nerolidol was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
membrane and skin penetration enhancement
Review literature repeatedly describes nerolidol as a terpene penetration enhancer that can increase transport across biological barriers, likely through lipid-disordering effects in membranes and stratum corneum domains.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
xenobiotic enzyme modulation
Mouse and in vitro studies reported increased CYP2B, CYP3A, and CYP2C activity or expression after trans-nerolidol exposure, supporting a plausible herb-drug interaction mechanism.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
doxorubicin accumulation in vitro
A breast-cancer-cell study found that trans-nerolidol increased intracellular doxorubicin accumulation and reduced migration in vitro, but this did not translate into improved tumor-growth control in vivo.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- Most functional literature discusses nerolidol broadly rather than cleanly separating trans from cis isomer outcomes.
- No human clinical trial specific to isolated trans-nerolidol was verified in this pass.
- A clear public dermal or inhalation exposure threshold specific to trans-nerolidol was not verified.
- Uncited placeholder values (dermal_limit_pct:20, sensitizing:true) removed on QA re-check 2026-07; no authoritative source found.
- 2026-07-13 re-verification: no trans-isomer-specific dermal limit exists in public sources; applied the RIFM/IFRA isomer-unspecified nerolidol fragrance maximum (2.02% average maximum reported use level in fine fragrance, IFRA 2007 survey data), which shares CAS 7212-44-4 with this record, as the closest verifiable proxy. This is an isomer-unspecified figure, not a trans-nerolidol-specific monograph value; sensitizing and penetration_enhancer left null as no isomer-specific classification was located.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.